These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3917453)

  • 1. Parkinson disease. Individualizing therapy.
    Feldman RG; Lannon MC
    Hosp Pract (Off Ed); 1985 Jan; 20(1):80A-80E, 80I, 80M, passim. PubMed ID: 3917453
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Psychosis in patient on bromocriptine and levodopa with carbidopa.
    Lipper S
    Lancet; 1976 Sep; 2(7985):571-2. PubMed ID: 60643
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychiatric symptoms with initiation of carbidopa-levodopa treatment.
    Lin JT; Ziegler DK
    Neurology; 1976 Jul; 26(7):699-700. PubMed ID: 945518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 5. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
    Kartzinel R; TEYCHENNE P; Gillespie MM; Perlow M; Gielen AC; Sadowsky DA; Calne DB
    Lancet; 1976 Aug; 2(7980):272-5. PubMed ID: 59850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on drug treatment of Parkinsonism.
    Winkelman AC
    Am Fam Physician; 1977 Jul; 16(1):118-20. PubMed ID: 18001
    [No Abstract]   [Full Text] [Related]  

  • 7. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine in parkinsonism. A long-term study.
    Lees AJ; Haddad S; Shaw KM; Kohout LJ; Stern GM
    Arch Neurol; 1978 Aug; 35(8):503-5. PubMed ID: 666607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine in Parkinson disease: further studies.
    Lieberman AN; Kupersmith M; Gopinathan G; Estey E; Goodgold A; Goldstein M
    Neurology; 1979 Mar; 29(3):363-9. PubMed ID: 571981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 12. [Diurnal worsening in Parkinson patients treated with levodopa].
    Piccini P; Del Dotto P; Pardini C; D'Antonio P; Rossi G; Bonuccelli U
    Riv Neurol; 1991; 61(6):219-24. PubMed ID: 1813974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled-release carbidopa-levodopa: old drug--new drug. Introduction.
    Koller WC
    Neurology; 1992 Jan; 42(1 Suppl 1):4-5; discussion 57-60. PubMed ID: 1549200
    [No Abstract]   [Full Text] [Related]  

  • 14. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304
    [No Abstract]   [Full Text] [Related]  

  • 16. How to achieve maximum benefit for the patient with Parkinson's disease.
    Greer M
    Geriatrics; 1976 Apr; 31(4):89-96. PubMed ID: 4356
    [No Abstract]   [Full Text] [Related]  

  • 17. [The treatment of Parkinson disease using the combination bromocriptine and levodopa].
    Dufresne JJ
    Rev Med Suisse Romande; 1990 Jun; 110(6):559-64. PubMed ID: 2367793
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause.
    Figà-Talamanca L; Gualandi C; Di Meo L; Di Battista G; Neri G; Lo Russo F
    Neurology; 1985 Feb; 35(2):258-61. PubMed ID: 3969217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
    Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.